The past, present and future of antifolates in the treatment of Plasmodium falciparum infection

J Antimicrob Chemother. 2006 Jun;57(6):1043-54. doi: 10.1093/jac/dkl104. Epub 2006 Apr 14.

Abstract

Chemotherapy remains the most important means of controlling malaria, one of the deadliest infectious parasitic diseases in the world. Antimalarial antifolates have been central for prophylaxis and treatment of malaria. This drug family was discovered in the 1940s, during the Second World War, and molecules that are currently in clinical use were discovered at that time. Since the 1940s, no new antimalarial antifolates have been developed that have reached Phase I/II stages. Limited work has been carried out to exploit the inhibition of the malaria folate pathway as a means of discovering new drugs. In this review, work carried out on antimalarial antifolates since the 1940s up to the present time is discussed in terms of discovery, clinical use, mode of action and mechanism of resistance. New concepts have been presented to improve antimalarial antifolate in vivo efficacy and to identify potent new antifolate agents.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use
  • Drug Resistance
  • Folic Acid Antagonists / pharmacology
  • Folic Acid Antagonists / therapeutic use*
  • Humans
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / prevention & control*
  • Plasmodium falciparum / drug effects

Substances

  • Antimalarials
  • Folic Acid Antagonists